 Vinyl ethers of nucleoside analogs |
| OF THE INVENTION The compounds of the present invention can exist as optical isomers. Both the ... |
|
| Nucleoside analogs |
| OF THE INVENTION The compounds of the present invention can exist as optical isomers. Both the ... |
|
| Hydrophobic multicomponent heparin conjugates, a preparing method and a use thereof |
| To accomplish those objectives, the present invention provides hydrophobic muiticomponent heparin ... |
|
| Gas permeable bioreactor and method of use |
| OF THE PREFERRED EMBODIMENTS Like numbered apparatus elements in FIGS. 1-11 are the same. R... |
|
| Method for treating diseases of the inner ear using adamantane derivatives |
| OF THE INVENTION As already mentioned, the use of adamantane derivatives is possible or ... |
|
| Polyalkylene oxide-containing urethane polyols with sulphonic acid groups |
| What is claimed is: 1. Sulphonic acid group-containing polyalkylene oxide-containing urethane ... |
|
| Herpes treatment |
| I claim: 1. A method for the control of herpes virus infections in man which comprises contacting ... |
|
| Dense star polymers and dendrimers |
| OF ILLUSTRATIVE EMBODIMENTS In the dense star polymers of the present invention, the core is ... |
|
| Glycerin derivatives and inhibition of blood PAF |
| OF THE INVENTION The glycerine derivatives of the invention are compounds of the formula ##STR3## ... |
|
| Oligonucleotide derivatives and production thereof |
| Gist In view of the state of the art as described above, the present inventors have developed an ... |
|
|
Methods for diagnosing sepsis
| Details |
Inventors: Tracey, Kevin J.; Wang, Haichao;
Assignee: North Shore-Long Island Jewish Research Institute (Great Neck, NY)
Primary Examiner: Romeo; David
Assistant Examiner: Brannock; Michael
Attorney, Agent or Firm:
There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment. |
|
DETAILED DESCRIPTION The present invention provides a pharmaceutical composition for treating conditions (diseases) mediated by the inflammatory cytokine cascade, comprising an effective amount of an antagonist or inhibitor of HMG1.
Preferably, the HMG1 antagonist is selected from the group consisting of antibodies that bind to an HMG1 protein, HMG1 gene antisense sequences and HMG1 receptor antagonists.
The present invention provides a method for treating a condition mediated by the inflammatory cytokine cascade, comprising administering an effective amount of an HMG1 antagonist.
In another embodiment, the inventive method further comprises administering a second agent in combination with the HMG1 antagonist, wherein the second agent is an antagonist of an early sepsis mediator, such as TNF, IL-1.
alpha.
, IL-1.
beta.
, MIF or IL-6.
Most preferably, the second agent is an antibody to TNF or an IL-1 receptor antagonist (IL-1ra).
The present invention further provides a diagnostic and prognostic method for monitoring the severity and predicting the likely clinical course of sepsis and related conditions for a patient exhibiting shock-like symptoms or at risk to exhibit symptoms associated with conditions mediated by the inflammatory cascade.
The inventive diagnostic and prognostic method comprises measuring the concentration of HMG1 in a sample, preferably a serum sample, and comparing that concentration to a standard for HMG1 representative of a normal concentration range of HMG1 in a like sample, whereby higher levels of HMG1 are indicative of poor prognosis or the likelihood of toxic reactions.
The diagnostic method may also be applied to other tissue or fluid compartments such as cerebrospinal fluid or urine.
Lastly, the present invention provides a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active fragment thereof.
|
|
Gene Therapy 
